Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Portfolio Pulse from
Teva Pharmaceuticals and Alvotech have announced the U.S. availability of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara®, for treating various conditions. The FDA has provisionally determined it will be interchangeable with Stelara® after April 30, 2025.
February 21, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech, in collaboration with Teva, has introduced SELARSDI™, a biosimilar to Stelara®, in the U.S. This marks a significant step in Alvotech's expansion in the U.S. market.
The introduction of SELARSDI™ in the U.S. market is a strategic move for Alvotech, potentially increasing its market presence and revenue in the biosimilar sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Teva Pharmaceuticals, in partnership with Alvotech, has launched SELARSDI™, a biosimilar to Stelara®, in the U.S. This could enhance Teva's market position in the biosimilar space.
The launch of SELARSDI™ strengthens Teva's biosimilar portfolio, potentially increasing its market share and revenues in the U.S. biosimilar market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80